Tumor necrosis factor-alpha enhances mRNA expression and secretion of interleukin-6 in cultured human airway smooth muscle cells by McKay, S. (Sue) et al.
 Am. J. Respir. Cell Mol. Biol. Vol. 23, pp. 103–111, 2000
Internet address: www.atsjournals.org
 
Tumor Necrosis Factor-
 
a
 
 Enhances mRNA Expression and Secretion
of Interleukin-6 in Cultured Human Airway Smooth Muscle Cells
 
Sue McKay, Stuart J. Hirst, Marion Bertrand-de Haas, Johan C. de Jongste, Henk C. Hoogsteden,
Pramod R. Saxena, and Hari S. Sharma
 
Departments of Pharmacology and Paediatrics-Respiratory Medicine, Sophia Children’s Hospital, Rotterdam; Department of Pulmonary 
Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands; and Department of Respiratory Medicine and Allergy,
The Guy’s, King’s College and St. Thomas’ Hospital Medical and Dental Schools, London, United Kingdom
 
Airway smooth muscle (ASM) is considered to be an end-tar-
get cell for the effects of mediators released during airway
wall inflammation. Several reports suggest that activated ASM
may be capable of generating various proinflammatory cyto-
kines. We investigated the effects of tumor necrosis factor
(TNF)-
 
a
 
, a potent proinflammatory cytokine, on cultured hu-
man ASM cells by examining the expression and release of the
cytokine interleukin (IL)-6, cell proliferation, and the expres-
sion pattern of c-
 
fos
 
 and c-
 
jun
 
, two nuclear proto-oncogenes
constituting the activator protein-1 transcription factor.
Growth-arrested cell monolayers were stimulated with human
recombinant TNF-
 
a
 
 in a concentration- and time-dependent
manner. TNF-
 
a
 
 stimulated the expression of IL-6 messenger
RNA (mRNA), which was detected after 15 min, reaching a
maximum at 1 h. IL-6 protein was readily detected in ASM
cell–conditioned medium after 2 h of TNF-
 
a
 
 stimulation. Pro-
tein levels increased in a time- and concentration-dependent
manner. Release of IL-6 elicited by TNF-
 
a
 
 was significantly
inhibited by dexamethasone, cycloheximide, and nordihy-
droguaiaretic acid (NDGA). TNF-
 
a
 
 did not alter DNA biosyn-
thesis up to 48 h or cell numbers up to 120 h. Northern blot
analysis of proto-oncogene expression revealed that c-fos and
c-jun mRNA levels were elevated after 30 min of TNF-
 
a
 
 incu-
bation with maximum levels at 1 h and 45 min, respectively.
Expression of c-fos mRNA was downregulated by NDGA. Four
hours of TNF-
 
a
 
 treatment resulted in translocation of c-jun im-
munofluorescence from the cytoplasm to the nucleus in hu-
man ASM cells. Our results suggest that despite the lack of a
mitogenic response to TNF-
 
a
 
, upregulation of primary re-
sponse genes in human ASM cells may account for the induc-
tion of proinflammatory cytokines, such as IL-6, in human air-
ways.
 
Asthma is a chronic disease of the airways characterized
by reversible airway obstruction and airway hyperrespon-
siveness. Important pathologic features of asthmatic air-
ways include inflammatory cell infiltration, epithelial shed-
ding, basement membrane thickening, and increased mass
of airway smooth muscle (ASM) (1–3). Infiltration of lym-
phocytes and granulocytes, especially eosinophils, and
their concomitant release of cytokines appear to play a
central role in mediating the airway inflammatory response
(4). Several inflammatory cell-derived cytokines have also
been implicated in ASM cell division and growth (5–7), and
may therefore be linked to the observed hyperplasia and
hypertrophy of smooth muscle in asthmatic airways (1, 2).
In addition to their contractile and proliferative proper-
ties, ASM cells may modulate airway inflammation by the
synthesis and secretion of proinflammatory secondary me-
diators, thereby acting as “immune effector” cells in the
perpetuation of the airway inflammatory reaction (8–12).
Tumor necrosis factor (TNF)-
 
a
 
 is a potent proinflam-
matory cytokine and its role as a potential mediator in
asthma has been well described (13, 14). It has been shown
in humans that inhaled TNF-
 
a
 
 increases bronchial respon-
siveness (15). TNF-
 
a
 
 can also modulate cultured ASM
cells to proliferate (6, 7). Another important biologic ac-
tion of TNF-
 
a
 
 is its ability to induce an influx of inflamma-
tory cells into tissues through either chemotactic mecha-
nisms or increased expression of adhesion molecules (16–18).
Interleukin (IL)-6, a pleiotropic cytokine, has proin-
flammatory effects relevant to airway wall inflammation
(19), including mucus hypersecretion (20), as well as stim-
ulation of hyperplasia and hypertrophy of cultured guinea
pig ASM cells (5). Expression of the IL-6 gene can be in-
duced in many different cell types after stimulation with
TNF-
 
a
 
 (21) and decreased by treatment with corticoste-
roids (22–24). The gene contains sequences for the serum
responsive element and the consensus sequences for tran-
scription factors such as activator protein (AP)-1 and nu-
clear factor kappa-B (NF-
 
k
 
B). These regulatory sequences
play an important role in transcriptional activation of the
IL-6 gene (25). TNF-
 
a
 
 can induce NF-
 
k
 
B and AP-1 in hu-
man lung, which could be of relevance for the expression
of IL-6 (18, 26, 27).
Several investigators have shown that the levels of both
TNF-
 
a
 
 and IL-6 are upregulated in patients with acute se-
vere asthma (28–30). However, the molecular mechanisms
involved in the relationship between TNF-
 
a
 
 and IL-6 gene
expression have not been investigated in airway inflamma-
tion. In this study, we investigated the effects of TNF-
 
a
 
 on
the expression and release of IL-6 by human ASM cells.
We also examined the messenger RNA (mRNA) expres-
sion pattern of the constituent proteins of the AP-1 tran-
scription factor complex, c-jun and c-fos. ASM cell prolif-
eration was also assessed in relation to TNF-
 
a
 
 and/or IL-6.
Furthermore, we determined whether the secretion of IL-6
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by human ASM cells was sensitive to inhibition by the glu-
cocorticosteroid dexamethasone, as well as the protein syn-
thesis inhibitor cycloheximide (CHX) and the lipoxygen-
ase pathway inhibitor nordihydroguaiaretic acid (NDGA).
 
Materials and Methods
 
Human ASM Cell Isolation and Culture
 
Human ASM cells were isolated and cultured as described previ-
ously (31, 32). Briefly, bronchial smooth muscle was dissected
from a fresh macroscopically normal lobar or main bronchus ob-
tained from patients who underwent surgery for lung carcinoma.
After removal of the epithelium, pieces of smooth muscle were
dissected free of adherent connective and parenchymal tissue un-
der aseptic conditions. Smooth muscle pieces were incubated in
Hanks’ balanced salt solution (Life Technologies BV, Breda, The
Netherlands) containing bovine serum albumin (BSA; 10 mg/ml),
collagenase (type XI, 1 mg/ml), and elastase (3.3 U/ml) (Sigma
BV, Zwijndrecht, The Netherlands) at 37
 
8
 
C in a humidified incu-
bator (ASSAB, model T154; Clean Air Techniek BV, Woerden,
The Netherlands) containing 5% CO
 
2
 
 in air. After enzymatic di-
gestion, the cell suspension was centrifuged and the pellet was
washed in Dulbecco’s modified Eagle’s medium (DMEM; Life
Technologies BV) containing 10% (vol/vol) fetal bovine serum
(FBS; Bio-Whitaker BV, Verviers, Belgium) supplemented with
sodium pyruvate (1 mM), nonessential amino-acid mixture
(1:100), gentamicin (45 
 
m
 
g/ml), penicillin (100 U/ml), streptomy-
cin (100 
 
m
 
g/ml), and amphotericin B (1.5 
 
m
 
g/ml) (Life Technolo-
gies BV). Cells were subsequently seeded at 2 
 
3
 
 10
 
5
 
 cells per 35-
mm dish and maintained in culture by replacing the medium every
72 h. After 10 to 14 d in culture, ASM cells grew to confluence and
they were then removed by trypsinization (0.5% trypsin; 0.02%
ethylenediaminetetraacetic acid [EDTA]; Life Technologies BV)
and subcultured into 25-cm
 
2
 
 tissue culture flasks. Cells were fur-
ther passaged into 75-cm
 
2
 
 tissue culture flasks. Confluent cells in
the fourth to sixth passages were used for experiments.
Immunocytochemical staining of confluent serum-deprived
primary cultures of human ASM cells, using monoclonal antibod-
ies to smooth muscle 
 
a
 
-actin and smooth muscle–myosin heavy
chain (Sigma BV) (31, 33), demonstrated that the cultures were
essentially free (
 
.
 
 95%) of other contaminating cell types.
 
Stimulation of ASM Cells
 
Human ASM cells were harvested from 75-cm
 
2
 
 flasks by treat-
ment with trypsin during passages 4 to 6. Cells were seeded into
24-well plastic tissue culture plates at a density of 3 
 
3
 
 10
 
4
 
 cells/
well and allowed to adhere for 24 h. To synchronize cellular
growth, human ASM cells were washed twice in phosphate buff-
ered saline (PBS; 140 mM NaCl, 2.6 mM KCl, 1.4 mM KH
 
2
 
PO
 
4
 
,
8.1 mM Na
 
2
 
HPO
 
4
 
.2H
 
2
 
O, pH 7.4) and cultured in serum-free
DMEM containing 1 
 
m
 
M insulin, 5 
 
m
 
g/ml transferrin, and 100 
 
m
 
M
ascorbate (Sigma BV) for 72 h. Using flow cytometric analysis of
human ASM cells stained with propidium iodide, we previously
found that 72 h of serum deprivation resulted in approximately
85% of human ASM cells remaining in the G
 
0
 
/G
 
1
 
 phase (S. McKay
and H. S. Sharma, unpublished observations). Growth-arrested
cell monolayers were stimulated with TNF-
 
a
 
 (Knoll AG, Lud-
wigshaven, Germany) in fresh FBS-free DMEM in a concentra-
tion-dependent (0, 1, 5, 10, 25, 50, 100, and 500 U TNF-
 
a
 
/ml; 24
h) and time-dependent (15, 30, 45 min, 1, 2, 4, 8, 16, 24, 48, 72, 96,
120 h; 50 U/ml TNF-
 
a
 
) manner. In a separate set of experiments,
serum-deprived cells were stimulated with human recombinant IL-6
(Promega, Leiden, The Netherlands) in fresh FBS-free DMEM in a
concentration-dependent (0, 1, 5, 10, 50 ng IL-6/ml; 72 h) manner.
An appropriate concentration of TNF-
 
a
 
 (50 U/ml) was se-
lected for further experiments. Where inhibitors were used, cells
were preincubated for 1 h with either dexamethasone (1 nM to
1 
 
m
 
M) (US Biochemicals and Amersham Nederland BV, ’s-Her-
togenbosch, The Netherlands), CHX (1 nM to 1,000 nM), or
NDGA (1 
 
m
 
M to 10 
 
m
 
M) (Sigma BV) before the addition of
TNF-
 
a
 
 for 1 h (c-fos mRNA expression), 2 and 4 h (IL-6 mRNA
expression), or 16 and 24 h (IL-6 protein assay). Cell-conditioned
medium (0.5 ml) was collected and stored at 
 
2
 
20
 
8
 
C until assayed
for IL-6 levels by enzyme-linked immunosorbent assay (ELISA).
To measure cell-associated IL-6 levels, human ASM cells
were lysed in single detergent lysis buffer (50 mM Tris-HCl, pH
8, 150 mM NaCl, 0.02% sodium azide, 1% Triton X-100, 1 
 
m
 
g/ml
aprotinin, 100 
 
m
 
g/ml phenylmethylsulfonyl fluoride) after 4 h
incubation in either serum-deprived medium or with TNF-
 
a
 
. The
lysate was stored at 
 
2
 
80
 
8
 
C until assayed for IL-6 levels by
ELISA.
ASM cell viability was determined immediately by mitochon-
drial-dependent reduction of the tetrazolium salt 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma BV)
to formazan as described previously (12, 32, 34). Cell monolayers
were washed in 0.5 ml PBS, MTT (200 
 
m
 
l in DMEM; final con-
centration, 0.5 
 
m
 
g/ml) was added to each well, and the cells were
incubated for 5 h before overnight solubilization in an additional
200 
 
m
 
l 10% sodium dodecyl sulfate in 0.1 M HCl. A 200-
 
m
 
l ali-
quot from each duplicate well was transferred to a 96-well micro-
plate, and the optical density (OD) was determined using an au-
tomated dual wavelength spectrophotometer (3550 microplate
reader; Bio-Rad, Veenendaal, The Netherlands) at a test wave-
length of 595 nm and a reference of 690 nm. Cell viability was ex-
pressed as arbitrary OD units.
 
Isolation of Total Cellular RNA
 
TNF-
 
a
 
–treated and –untreated human ASM cells were washed in
PBS and directly lysed in guanidinium thiocyanate buffer. The ly-
sate was repeatedly passed through a 23-gauge needle in order to
shear the genomic DNA. Total cellular RNA was isolated using
the method described previously (31, 35). The RNA concentra-
tion was estimated by OD measurements and a DNA/protein ra-
tio of 
 
> 
 
1.8 was accepted. Furthermore, the quality of RNA was
tested on a denaturing formaldehyde agarose gel. RNA samples
were stored at 
 
2
 
20
 
8
 
C until processed for reverse transcriptase/
polymerase chain reaction (RT-PCR) and Northern blot analysis.
 
RT-PCR
 
RT-PCR was performed to detect IL-6 mRNA expression in cul-
tured human ASM cells and subsequently to prepare a human-spe-
cific complementary DNA (cDNA) probe. Reverse transcription
of 5 
 
m
 
g of total RNA was performed using avian myleoblastosis
virus (AMV) reverse transcriptase (20 U) (HT Biotechnologies,
Cambridge, UK), 1 mM of deoxyadenosine triphosphate (dATP),
deoxycytidine triphosphate (dCTP), deoxyguanosine triphosphate
(dGTP), and deoxythymidine triphosphate (dTTP), 2 
 
m
 
g oligo(dT)
 
12-18
 
primer (Pharmacia Biotechnologies, Woerden, The Netherlands),
1 U/
 
m
 
l RNase inhibitor (Promega), 5.0 mM MgCl
 
2
 
, 50 mM KCl,
25 mM Tris-HCl (pH 8.3), and 2.0 mM dithiothreitol in a total vol-
ume of 50 
 
m
 
l. Oligo(dT) and dissolved RNA were incubated at 70
 
8
 
C
for 10 min and placed on ice. Subsequently, the remaining ingre-
dients were added and samples were incubated at 42
 
8
 
C for 40 min.
Five microliters of the cDNA samples were amplified. PCR
was performed using 0.5 
 
m
 
M concentration of forward and re-
verse primers (Life Technologies BV); dATP, dGTP, dCTP, and
dTTP at a final concentration of 0.25 mM each; 0.5 U 
 
Taq
 
 poly-
merase (Perkin Elmer, Gouda, The Netherlands); 1.5 mM MgCl
 
2
 
;
50 mM KCl; 10 mM Tris-HCl (pH 8.3) in a final volume of 20 
 
m
 
l.
Oligonucleotide primers for human IL-6 were sense primer, 5
 
9
 
-
TACATCCTCGACGGCATCTCA-3
 
9
 
, and anti-sense primer,
5
 
9
 
-AGTTGTCATGTCCTGCAGCCA-3
 
9
 
, giving rise to a PCR
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product of 398 bp. Amplification of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) using 5
 
9
 
-GGCCATCCACAGTCT-
TCTGGGT-3
 
9
 
 and 5
 
9
 
-CCGAGCCACATCGCTCAGAC-AC-3
 
9
 
primers, giving rise to a product of 594 bp, was used as reference.
The PCR was carried out in a PTC-100 programmable thermal
controller (MJ Research Inc., Watertown, MA) at 94
 
8
 
C for an ini-
tial 10 min followed by 35 cycles of denaturation at 94
 
8
 
C for 1 min,
annealing at 55
 
8
 
C for 30 s, and extension at 72
 
8
 
C for 90 s. Final
extension was for 10 min at 72
 
8
 
C. Products were resolved by elec-
trophoresis on a 1% agarose ethidium bromide–stained gel and
then visualized using ultraviolet luminescence and photographed.
The PCR product was purified using a Wizard PCR purification
system (Promega) before sequencing in an automated Applied
Biosystems Prism 310 genetic analyzer (Perkin Elmer, Nieu-
wekerk a/d Ijssel, The Netherlands). Cycle sequencing reactions
using an ABI prism dye terminator kit were performed according
to the manufacturer’s instructions (Perkin Elmer). The IL-6 PCR
product was cloned into the pGEM-T easy plasmid vector and
transformed into JM109 cells (Promega). The insert positive
clones were processed for plasmid DNA isolation using a Wizard
DNA purification kit (Promega).
 
Northern Blot Analysis
 
For Northern hybridization, samples of total RNA (10 
 
m
 
g) were
denatured at 65
 
8
 
C in a formaldehyde containing loading buffer
and size-fractionated on a 1% agarose gel containing 2.2 M form-
aldehyde. Ethidium bromide–stained gels were photographed,
and RNA was transferred onto hybond-N membrane (Amer-
sham Nederland BV) by the alkaline downward capillary transfer
method (36). The filters were air-dried and UV cross-linked in a
gene linker (Bio-Rad Laboratories BV). Blots were hybridized as
described previously (31). The cDNA probes used for hybridiza-
tion were human IL-6 (360-bp fragment), mouse c-fos (2.1-kb frag-
ment), and mouse c-jun (2.6-kb fragment). A GAPDH cDNA
probe (American Type Culture Collection, Rockville, MD) was
used to rehybridize membranes for reference purposes. Hybrid-
ization signals were quantified by scanning laser densitometry us-
ing the Ultroscan XL enhanced laser densitometer (LKB, Bromma,
Sweden). Signals were normalized with respect to GAPDH
mRNA values and expressed as relative OD in TNF-
 
a
 
–stimu-
lated cells versus control cells.
 
Measurement of IL-6 Protein Levels by ELISA
 
IL-6 protein levels in ASM cell lysates and cell-conditioned me-
dium were determined using a solid-phase sandwich ELISA
(Medgenix, Breda, The Netherlands). Samples of cell-condi-
tioned medium were diluted until the level of IL-6 was within the
linearity limits of the standard curve of the assay. Subsequently,
the samples were preincubated with IL-6 capture antibody fol-
lowed by biotinylated IL-6 detecting antibody. After addition of
the streptavidin-peroxidase conjugate (Central Laboratory for
Blood Transfusion, Amsterdam, The Netherlands), tetramethyl-
benzidine (ICN Biomedicals Inc., Costa Mesa, CA) was added
and the absorbance of the resulting colored product was mea-
sured at 450 nm using an automated spectrophotometer (Bio-Rad
Laboratories BV). The concentration of IL-6 was expressed in
nanograms per milliliter. The detection limit of the IL-6 ELISA
method was 50 pg of IL-6/ml. No correction for cell number vari-
ation was made because the cells were serum deprived 16 to 24 h
after plating out, allowing insufficient time for proliferation.
 
Evaluation of Cellular Proliferation
 
[
 
3
 
H]Thymidine incorporation assay.
 
 Effects of recombinant
TNF-
 
a
 
 or IL-6 on DNA biosynthesis was evaluated by incorpora-
tion of [methyl-
 
3
 
H]thymidine (Amersham Nederland BV). Con-
fluent cells in the fourth passage were washed in PBS, detached
by trypsinization, and transferred into 24-well plates at a seeding
density of 6 
 
3
 
 10
 
4
 
 cells/well. After 24 h, the subconfluent cell
monolayers were growth arrested as described previously. Cells
were incubated with [methyl-
 
3
 
H]thymidine (1 
 
m
 
Ci/well) in either
fresh FBS-free DMEM (control) or DMEM containing TNF-
 
a
 
(50 U/ml) for 16, 24, or 48 h, or IL-6 (0, 1, 5, 10, 50 ng/ml) for 72 h
in order to assess DNA synthesis. After stimulation, the cells
were washed in PBS, fixed with ice-cold methanol, and exposed
to ice-cold trichloroacetic acid (5% wt/vol). The acid-insoluble
fraction was lysed in 0.3 M NaOH, and the incorporated radioac-
tivity was determined by liquid scintillation spectrometry in a
Packard 1500 Tri-carb liquid scintillation analyzer (Packard-
Becker BV, Delft, The Netherlands).
 
Cell counting.
 
 Cells were incubated in either fresh FBS-free
DMEM, FBS-free DMEM containing TNF-
 
a
 
 (50 U/ml) for 24,
48, 72, 96, or 120 h, or FBS-free DMEM containing IL-6 (0, 1, 5,
10, or 50 ng/ml; 7 d). After stimulation, the cell-conditioned me-
dium was removed, and the cells were dispersed in 50 
 
m
 
l of
trypsin-EDTA by incubating at room temperature for 10 min.
Cells were counted in a Bürker hemocytometer (Bürker, Marien-
feld, Germany) using the trypan blue dye (Sigma BV) exclusion
method.
 
Immunocytochemistry
 
An affinity-purified rabbit polyclonal antibody against human
c-jun (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was used
to demonstrate the cellular localization of the AP-1 transcription
factor in human ASM cells stimulated with TNF-
 
a
 
. Cells were al-
lowed to attach to multiwell slides for 24 h in FBS-containing me-
dium and were subsequently synchronized before stimulation
with TNF-
 
a
 
 (50 U/ml) for 2 or 4 h, or FBS-free medium. After
two washes in ice-cold PBS, the cells were fixed in ice-cold meth-
anol and permeabilized in PBS containing 0.5% Tween-20. Non-
specific binding was blocked by incubating the cells in PBS con-
taining 10% serum and 5% BSA, the cells were then washed and
subsequently incubated with c-jun antibody in a dilution of 1:100;
the negative control cells were not incubated with the primary
antibody. After incubation, the cells were washed twice in PBS/
Tween and further incubated with a fluorescein isothiocyanate
(FITC)-conjugated antirabbit antibody (Santa Cruz Biotechnol-
ogy). Unbound antibody was washed away using PBS and the
sections were mounted in glycerol. Specimens were visualized un-
der a microscope equipped with fluorescence ultraviolet optics
(Carl Zeiss BV, Weesp, The Netherlands) and photographed.
 
Statistical Analysis
 
Data in the text and figures are expressed as mean 
 
6
 
 standard er-
ror of the mean (SEM) of observations from 
 
n
 
 patients. Statistical
analysis was performed by using the two-tailed, independent sam-
ple t test. Significance was accepted at P , 0.05.
Results
IL-6 mRNA Expression in Relation to TNF-a
To examine IL-6 mRNA expression in human ASM cells
treated with TNF-a (50 U/ml) for 1, 2, or 4 h, we per-
formed RT-PCR employing human-specific IL-6 oligonu-
cleotide primers. Agarose gel electrophoresis revealed PCR
products of 398 bp in size. The PCR product was purified
and subjected to DNA sequencing, which confirmed that
the amplified PCR product was indeed IL-6, with a 100%
sequence homology to the human IL-6 cDNA, as reported
previously by Tonouchi and coworkers (37). The IL-6
PCR product was subsequently cloned into a pGEM-T
easy vector, and the recombinant plasmid DNA encoding
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IL-6 was used as a probe to detect and quantify IL-6
mRNA by Northern blot analysis. Densitometric analysis
of Northern blots showed that TNF-a induced the expres-
sion of mRNA encoding IL-6 after 15 min of stimulation
with a maximal induction at 1 h and then the expression
decreased gradually (Figure 1). The gene remained slightly
upregulated for up to 16 h.
Release of IL-6 Protein in Response to TNF-a
A concentration-dependent increase in the release of IL-6
protein from human ASM cells was found after stimula-
tion with TNF-a for 24 h (Figure 2). The highest IL-6 pro-
duction occurred in response to 500 U/ml of TNF-a. Con-
ditioned media derived from serum-deprived, untreated
ASM cells contained very low (6 0.25 ng/ml) levels of IL-6
protein. To verify that TNF-a–stimulated human ASM
cells release the de novo synthesized IL-6, we also mea-
sured its levels in the cell lysates of stimulated and unstim-
ulated control cells. IL-6 levels in cell lysates of unstimu-
lated ASM cells were negligible (0.10 6 0.01 ng/ml). MTT
reduction assays showed that ASM cell viability was not
affected by TNF-a (up to 500 U/ml; untreated cells, 0.24 6
0.02 versus TNF-a–treated cells, 0.26 6 0.03 OD units, n 5
4, P , 0.05).
In a second set of experiments, we found that TNF-a (50
U/ml) caused a time-dependent increase in IL-6 protein in
the ASM cell–conditioned media (Figure 3). IL-6 could be
detected after just 2 h of stimulation with TNF-a and con-
tinued to increase before reaching a plateau around 48 h.
The levels remained elevated for up to 120 h of stimulation.
IL-6 levels were significantly higher in the conditioned me-
dia derived from TNF-a–treated ASM cells compared with
untreated cells at all the time points studied.
Influence of Inhibitors on IL-6 Expression and Secretion
In Figure 4, the effects of dexamethasone and CHX on the
expression of IL-6 mRNA from untreated and TNF-a–
treated (50 U/ml) cells are shown. Interestingly, treatment
with CHX (1 mM) resulted in increased IL-6 mRNA levels
comparable to those present during TNF-a treatment. When
cells were incubated with both TNF-a and CHX, IL-6
mRNA levels were further increased by 2.8-fold. How-
ever, dexamethasone significantly inhibited the TNF-a–
induced expression of IL-6 mRNA by more than 50%.
Addition of TNF-a (50 U/ml) to ASM cell cultures pre-
incubated with dexamethasone (1 nM to 1 mM) showed a
concentration-dependent inhibition in the production of
IL-6 from these cells measured by ELISA (Figure 5A).
Dexamethasone, at a concentration of 100 nM, signifi-
cantly decreased the TNF-a–induced IL-6 protein levels
by 83% from 3.98 6 0.81 to 1.17 6 0.18 ng/ml. Levels of
IL-6 in cell-conditioned medium after treatment with dex-
amethasone at 1 mM were not significantly different than
IL-6 levels in conditioned medium from unstimulated cells
(n 5 4, P , 0.05). Preincubation of human ASM cells with
CHX (1 nM to 1 mM) also showed a concentration-depen-
dent inhibition in the production of IL-6 protein by cells
stimulated with an optimal concentration (50 U/ml) of
TNF-a for 24 h (Figure 5B). A total of 1 mM of CHX re-
duced the release of IL-6 by 25% from 3.08 6 0.86 to 2.28 6
0.62 ng/ml (n 5 4, P , 0.05) (Figure 5B).
The lipoxygenase pathway inhibitor NDGA reduced the
secretion of IL-6 protein at a concentration of 1 mM. As
shown in Figure 6, NDGA significantly inhibited the TNF-a–
induced production of IL-6 at 4, 8, and 16 h by 60.9 6 13.3,
42.3 6 7.3, and 41.9 6 6.8%, respectively (n 5 3, P ,
0.05), whereas IL-6 levels in cell-conditioned medium af-
Figure 1. Northern blot analysis of IL-6 mRNA expression. Hu-
man ASM cells were treated with TNF-a for the times indicated
at the top of each lane, and total cellular RNA was extracted and
subjected to Northern hybridization using human IL-6 cDNA
probes as described in MATERIALS AND METHODS. Rehybridiza-
tion with a GAPDH cDNA probe (lower panel) was performed
for reference purposes.
Figure 2. TNF-a concentration-dependent production of IL-6 by
human ASM cells. Growth-arrested ASM cells were stimulated
in the absence (control) or presence of varying concentrations of
TNF-a for 24 h. Data represent the mean 6 SEM of triplicate
values from independent experiments using conditioned medium
from ASM cells cultured from four different patients.
Figure 3. Time-dependent production of IL-6 protein by TNF-a–
stimulated human ASM cells. Growth-arrested human ASM cells
were stimulated with 50 U/ml of TNF-a (circles) for various time
points. Control cells (squares) received only serum-free medium.
Data represent the mean 6 SEM of triplicate values from inde-
pendent experiments using conditioned medium from ASM cells
cultured from four patients. *P < 0.05 as compared with respec-
tive controls.
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ter treatment with NDGA alone were not significantly dif-
ferent from unstimulated control cells.
We also examined the effects of dexamethasone and
CHX on cell viability by using the MTT reduction assay.
Performing treatment with the previously mentioned re-
agents, cell viability was not significantly affected up to 24 h
of stimulation. For instance, in TNF-a 1 dexamethasone
and TNF-a 1 CHX–treated cells, the MTT reduction as-
say values were 0.28 6 0.01 and 0.28 6 0.01 versus 0.27 6
0.01 ODU (n 5 4).
Effects of TNF-a and IL-6 on ASM Cell Proliferation
To ascertain whether human recombinant TNF-a induces
cell proliferation, [3H]thymidine incorporation up to 48 h
and changes in cell number during 120 h of incubation
were determined. Treatment of serum-deprived human
ASM cells with TNF-a (50 U/ml) up to 48 h of incubation
did not induce DNA biosynthesis as compared with un-
treated control cells (data not shown). Furthermore, TNF-a
incubation did not significantly increase ASM cell number
as compared with controls (Figure 7).
To establish whether human recombinant IL-6 induces
ASM cell proliferation, [3H]thymidine incorporation and
changes in cell number were determined using varying con-
centrations of IL-6 (including the concentration found to be
secreted by TNF-a–stimulated ASM cells). Data shown in
Figure 8 depict that IL-6 did not significantly alter the DNA
biosynthesis as well as cell number in human ASM cells.
Expression of c-fos and c-jun Proto-oncogenes in
Relation to TNF-a
Representative Northern blots showing the expression
pattern of the proto-oncogenes c-fos and c-jun in TNF-a–
stimulated human ASM cells are shown in Figure 9. Densi-
tometric analysis of the Northern blots revealed that TNF-a
induced the expression of mRNAs encoding c-fos and c-jun
after 30 min of stimulation. The induction of c-fos mRNA
was transient and reached a maximum at 60 min followed
by an abrupt decline. However, the expression of c-jun
reached a maximum level at 45 min of TNF-a stimulation
and levels remained elevated. FBS (10%) also induced the
expression of c-jun mRNA. Furthermore, in an attempt to
examine whether NDGA could block the c-fos expression,
we found that at 1 and 10 mM concentrations, TNF-a–
induced expression levels of c-fos mRNA were decreased
by 60.8 6 12.1 and 69 6 9%, respectively (Figure 10).
Immunocytochemical Localization of C-JUN in
Human ASM Cells
Figure 11 illustrates representative microscopic fields of
either serum-deprived or TNF-a–treated human ASM
cells stained with antibodies recognizing C-JUN protein.
At 2 h of TNF-a (50 U/ml) stimulation, C-JUN was local-
ized in the cytoplasm of human ASM cells (Figure 11, mid-
dle panel). After 4 h of TNF-a stimulation, the C-JUN was
translocated to the nuclei, giving rise to prominent staining
in the nuclei rather than in the cytoplasm (Figure 11, right
panel). Untreated cells showed a faint background immu-
nofluorescence in their cytoplasm and nucleus (Figure 11,
left panel). Additionally, the negative controls, prepared
by omitting the primary antibody C-JUN, showed no im-
munofluorescence.
Figure 4. Effects of CHX and dexa-
methasone on IL-6 mRNA expression.
Human ASM cells were pretreated
with 1 mM of either CHX or dexa-
methasone (DEX) for 1 h before in-
cubation with or without TNF-a for
2 h. Total cellular RNA was extracted
and subjected to Northern hybridiza-
tion using human IL-6 cDNA probe
as described in MATERIALS AND METH-
ODS. Rehybridization with a GAPDH
cDNA probe (lower panel) was per-
formed for reference purposes.
Figure 5. Effects of dexamethasone and cycloheximide on IL-6
release from TNF-a–treated human ASM cells. Growth-arrested
human ASM cells were incubated with 50 U/ml of TNF-a in the
presence of increasing concentrations of dexamethasone (A) or
cycloheximide (B) as described in MATERIALS AND METHODS.
Data represent the mean 6 SEM of triplicate values from inde-
pendent experiments using conditioned medium from ASM cells
from four patients. *P < 0.05 compared with TNF-a–stimulated
cells in the absence of an inhibitor.
Figure 6. Effect of NDGA on TNF-a–induced release of IL-6.
Growth-arrested human ASM cells were incubated with 50 U/ml
of TNF-a in the presence of 1 mM NDGA as described in MATE-
RIALS AND METHODS. Data represent the percent mean 6 SEM in-
hibition of TNF-a–induced IL-6 production by NDGA. IL-6 pro-
duction in NDGA-treated cells was significantly (P < 0.05)
inhibited at 4, 8, and 16 h of incubation. Data were calculated
from quadruplicate values from three independent experiments
(three different patients).
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Discussion
Our study shows that human ASM cells in culture can be
stimulated by TNF-a to express and release a proinflam-
matory cytokine, IL-6, and that this effect is concentration
and time dependent. IL-6 protein and mRNA levels re-
mained very low in unstimulated ASM cells, suggesting
that an inducible rather than a constitutive mechanism is
involved. The concentrations of TNF-a at which signifi-
cant IL-6 production by human ASM cells were observed
were within the range likely to be present during airway
inflammation (30, 38).
Recently, several groups have shown that, in addition
to contractile responses, ASM cells are potentially capable
of modulating airway inflammation by synthesizing and
secreting proinflammatory secondary mediators like IL-8,
eotaxin, regulated on activation, normal T cells expressed
and secreted (RANTES), and granulocyte-macrophage
colony-stimulating factor (GM-CSF) (8–12). Thus, ASM
cells may also act as “immune effector” cells in perpetuat-
ing airway inflammation. Similarly, our results suggest that
human ASM may contribute directly to airway inflamma-
tion by interacting with TNF-a, a proinflammatory cyto-
kine found to be upregulated in symptomatic asthmatic
airways, by the production and release of the cytokine IL-6.
Stimulation of human ASM cells with IL-1a, transforming
growth factor-b1, and CD40 ligand also leads to the pro-
duction of IL-6 (18, 39). IL-6 is a 21-kD pleiotropic cyto-
kine that is produced by a variety of cells, including airway
epithelial cells (40), lung fibroblasts (41), macrophages
and monocytes (42), and vascular smooth muscle cells
(43). It has a number of proinflammatory properties that
could be relevant in the development and perpetuation of
airway inflammation during asthma, including the termi-
nal differentiation of B cells into antibody-producing cells
(44), upregulation of IL-4–dependent immunogloblin E
production (45), and stimulation of cytotoxic T-cell differ-
entiation (46).
A potential mechanism for the induction of IL-6 gene
expression could involve events such as the activation of
Figure 7. Proliferation of human ASM cells in relation to TNF-a.
Growth-arrested human ASM cells were stimulated with 50 U/ml
TNF-a for 24, 48, 72, 96, and 120 h, and cellular proliferation was
assessed by cell counting in relation to nonstimulated cells using a
hemocytometer. Values are represented as mean percent change
in cell numbers relative to controls 6 SEM of four measurements
from four separate experiments.
Figure 8. Proliferation of human ASM cells in relation to IL-6.
Growth-arrested human ASM cells were stimulated with IL-6 (0,
1, 5, 10, or 50 ng/ml) for 72 h or 7 d, and cellular proliferation was
assessed by thymidine incorporation (open bars) or cell counting
(hatched bars), respectively. Values are represented as dpm/well
(left y-axis) or mean percent change in cell numbers (right y-axis)
relative to controls 6 SEM of four measurements from two sepa-
rate experiments.
Figure 9. Northern blot analysis of c-fos and c-jun expression in
human ASM cells treated with TNF-a. Total RNA samples from
control and TNF-a–treated human ASM cells at various time
points were subjected to Northern hybridization with radiolabeled
cDNA probes as described in MATERIALS AND METHODS. Repre-
sentative Northern blots for c-fos (left panel, 2.2 kb mRNA) and
c-jun (right panel, 2.3 kb mRNA) are shown. Serum-deprived ASM
cells were incubated with TNF-a (50 U/ml) for the times indi-
cated at the top of each panel. Rehybridization of each filter with
a GAPDH cDNA probe (lower bands) was performed for refer-
ence purposes. Each experiment was repeated at least four times
using human ASM cells originating from different individuals.
Figure 10. Northern blot analysis of c-fos
expression in human ASM cells treated
with TNF-a in the presence or absence of
NDGA. Total RNA samples from TNF-
a–treated (1 h) human ASM cells in the
presence or absence of NDGA were sub-
jected to Northern hybridization with ra-
diolabeled c-fos probes as described in
MATERIALS AND METHODS. A representa-
tive Northern blot for c-fos (2.2 kb mRNA,
lower panel) is shown. Incubation condi-
tions are indicated at the top of the panel. Rehybridization with a
GAPDH cDNA probe (lower panel) was performed for refer-
ence purposes. Each experiment was repeated at least three times
using human ASM cells originating from different individuals.
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the AP-1 transcription factor binding site on the IL-6 gene.
The promoter region of the IL-6 gene has been shown to
contain two AP-1 binding sites in addition to a number of
other functionally important elements (25). The transcrip-
tion factor AP-1 is a heterodimer constituting the onco-
proteins resulting from c-fos and c-jun gene translation.
AP-1 may be activated by various cytokines, including
TNF-a, via different types of protein tyrosine kinases and
mitogen-activated protein (MAP) kinases, which subse-
quently activate a cascade of intracellular kinases (47),
leading to the upregulation of the IL-6 gene. We have
shown in this study that the mRNAs for the c-fos and c-jun
proto-oncogenes are upregulated by TNF-a stimulation of
human ASM cells in vitro. Additionally, we observed that
TNF-a–induced c-fos mRNA expression could be inhib-
ited by NDGA. The subsequent induction of IL-6 mRNA
and secretion of IL-6 protein were also inhibited. Further-
more, immunoreactive C-JUN was localized in the cyto-
plasm of cells treated with TNF-a for 2 h, and mainly in
the nucleus of cells after 4 h of treatment, suggesting that
the induced expression and translocation of AP-1 could
play a role in the observed gene expression for IL-6 in hu-
man ASM cells.
As corticosteroids are known to have potent anti-in-
flammatory effects and are clinically effective in suppress-
ing airway inflammation, we also determined whether dex-
amethasone was capable of inhibiting TNF-a–mediated
expression and secretion of IL-6 by human ASM cells. We
found that IL-6 gene expression and protein secretion by
human ASM cells was significantly decreased but not com-
pletely abolished by treatment with dexamethasone. The
precise mechanism of this downregulation has not been
determined in ASM cells, but it has been demonstrated in
HeLa cells to be due to the binding of ligand-activated glu-
cocorticoid receptor to the transcriptional regulatory re-
gions of the IL-6 promoter (22). Zitnik and coworkers (24)
and Tobler and colleagues (48) suggested that dexametha-
sone exerts its action mainly by decreasing the stability of
IL-6 mRNA through AUUUA-rich motifs in the 39 un-
translated region. Dexamethasone has also been shown to
inhibit the production of several other proinflammatory
cytokines, including GM-CSF, IL-8, and RANTES in hu-
man ASM cells (8, 10, 12). This suggests that ASM could
be another important therapeutic target for the anti-in-
flammatory effects of steroids (49). Surprisingly, the inhi-
bition by dexamethasone is variable for the previously
mentioned cytokines. GM-CSF production by human
ASM cells is completely abolished by 100 nM of dexa-
methasone, whereas the inhibition of RANTES and IL-8
production did not exceed 50% (8, 10, 12). In our experi-
ments, we could decrease the effect of TNF-a on IL-6 pro-
duction by 83% with 100 nM of dexamethasone.
The molecular basis of dexamethasone-mediated inhi-
bition of GM-CSF gene expression has been reported to
involve post-transcriptional destabilization of GM-CSF
mRNA (48). On the other hand, inhibition of IL-6 and IL-8
gene expression and protein synthesis have been shown to
involve both transcriptional inhibition and post-transcrip-
tional destabilization mechanisms by dexamethasone (22,
24, 48, 50, 51). Kwon and associates (52) reported that dex-
amethasone did not affect the TNF-a–induced RANTES
mRNA half-life in eosinophils, suggesting that purely tran-
scriptional inhibition mechanisms are responsible. The de-
gree of involvement of transcriptional inhibition and/or
post-transcriptional destabilization mechanisms may ac-
count for the variation in the observed dexamethasone-
induced inhibition in cytokine expression and secretion by
human ASM cells.
CHX (100 nM), a protein synthesis inhibitor, signifi-
cantly reduced, but did not abolish, IL-6 protein production
by TNF-a–stimulated human ASM cells. It is very likely
that 1 mM of CHX was insufficient to completely inhibit de
novo synthesis of IL-6. Also, we found that the increased re-
lease of IL-6 into the conditioned medium was due to the de
novo synthesized IL-6 and not due to the release of pre-
formed IL-6. This is evident from the ELISA data, which
show that ASM cells store a negligible amount of IL-6.
To determine if the remaining protein production was a
result of an inhibited mRNA degradation pathway, ASM
cells were incubated with either TNF-a, CHX, or a combi-
nation of TNF-a and CHX, and IL-6 mRNA expression
was assessed by Northern blot analysis. We found that in
Figure 11. Immunocytochemical
localization of C-JUN in TNF-a–
treated human ASM cells. Immu-
noreactive C-JUN was localized in
TNF-a–treated ASM cells using
an affinity purified human C-JUN
polyclonal antirabbit antibody and
FITC-conjugated secondary anti-
body as described in MATERIALS
AND METHODS. Translocation of
C-JUN to the nucleus of human
ASM cells after 4 h of stimulation
with TNF-a was observed. Cells
were fixed after treatment with se-
rum-depleted medium (left panel,
t 5 0, control) or TNF-a (50 U/
ml) for 2 h (middle panel) or 4 h
(right panel), and then subjected
to immunofluorescence staining.
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CHX-treated (1 mM) human ASM cells, IL-6 mRNA was
expressed to the same extent as in TNF-a–treated cells.
The combined treatment with CHX and TNF-a led to an
almost threefold increase in mRNA for IL-6 compared
with treatment with either CHX or TNF-a alone. Our re-
sults suggest that the inhibition of protein synthesis by
CHX may also involve the inhibition of mRNA degrada-
tion pathway via a limited synthesis of RNase activity, as
advocated previously (40). This can lead to an accumula-
tion of IL-6 mRNA in human ASM cells, which can subse-
quently lead to higher levels of IL-6 protein in the pres-
ence of CHX.
Radiolabeled thymidine incorporation demonstrated
that TNF-a (50 U/ml) had no immediate mitogenic effect
on human ASM cells in this study, in agreement with Bel-
visi and coworkers (53) but in contrast to work published
by Amrani and colleagues (7). This inconsistency may be
explained by taking into account that Amrani and cowork-
ers (7) included 0.3 or 3% serum in their culture medium,
whereas our culture medium was completely free of se-
rum. TNF-a and growth factors (present in serum) acti-
vate MAP kinases, MAP kinases being key transducers of
extracellular signals in proliferation and differentiation
pathways. Signals activated by these varying stimuli may
converge to induce proliferation in a synergistic manner,
possibly explaining the proliferative response to TNF-a.
Also, Stewart and colleagues (6) found a mitogenic response
to TNF-a at very low concentrations (0.3 to 30 pM) in hu-
man ASM cells, whereas at a higher concentration (300
pM), this mitogenic effect was abolished. De and cowork-
ers (5) have reported that IL-6 causes hyperplasia and hy-
pertrophy of cultured guinea pig ASM cells at concentra-
tions comparable to those present in the conditioned medium
of TNF-a–treated cells in this study. We found, however,
that human recombinant IL-6 at concentrations ranging
between 1 and 50 ng/ml was not mitogenic for human
ASM cells. Therefore, it could be stated here that the con-
tinuing time-dependent accumulation of IL-6 in the cell-
conditioned media in this study did not exhibit an autocrine
mitogenic effect on the cells. Apparently, the upregulation
of c-fos and c-jun, proteins forming the AP-1 transcription
factor that is normally associated with cellular prolifera-
tion, is not sufficient to cause human ASM cells to prolif-
erate but is probably involved in other processes, such as
regulating the inflammatory response through upregulation
of proinflammatory cytokines such as IL-6 (47).
A number of cells involved in the inflammatory response
in asthma are important sources of proinflammatory cyto-
kines such as TNF-a and come into close proximity to the
smooth muscle layer. They may be capable of releasing con-
centrations of TNF-a that can stimulate AP-1 regulated ex-
pression and release of IL-6 from cells. Our data suggest a
potentially important role for TNF-a and smooth muscle-
derived IL-6 in airway inflammation in asthma. The precise
role of IL-6 released from human ASM in the pathogenesis
of asthma and/or other pulmonary disorders is unclear, but
the capacity of ASM to produce IL-6 suggests that the cells
could participate in perpetuating or regulating local inflam-
matory events in the airways.
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